Based on the available information, Yervoy, also known as ipilimumab, is a type of immunotherapy that can be used to treat melanoma, a type of skin cancer. When combined with other drugs, Yervoy can offer several benefits to patients.

One significant benefit of combining Yervoy with other drugs is improved efficacy. According to the Cure Melanoma website, combining Yervoy with nivolumab, another type of immunotherapy, has been shown to improve response rates and progression-free survival in patients with advanced melanoma [2]. The European Medicines Agency also notes that combining Yervoy with nivolumab has been shown to improve overall survival in patients with advanced melanoma [3].

Another benefit of combining Yervoy with other drugs is that it may help to reduce the risk of resistance to treatment. According to Drug Patent Watch, combining Yervoy with other drugs can help to prevent the development of resistance to treatment, which can occur when cancer cells evolve to overcome the effects of a particular drug [1].

It's worth noting that combining Yervoy with other drugs can also increase the risk of side effects. According to the Cure Melanoma website, combining Yervoy with nivolumab can increase the risk of severe side effects, such as colitis, hepatitis, and endocrine dysfunction [2]. As such, patients receiving combination therapy with Yervoy should be closely monitored for signs of toxicity.

In summary, combining Yervoy with other drugs can offer several benefits to patients with melanoma, including improved efficacy and a reduced risk of resistance to treatment. However, it's important to note that combination therapy can also increase the risk of side effects, and patients should be closely monitored for signs of toxicity.

Sources:

* <https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY>
* <https://www.curemelanoma.org/patient-eng/melanoma-treatment/combination-therapy-for-melanoma/nivolumab-opdivo-ipilimumab-yervoy>
* <https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy>